Literature DB >> 24363525

Clinical significance of serum procalcitonin in patients with ulcerative colitis.

Shigeo Koido1, Toshifumi Ohkusa1, Kazuki Takakura1, Shunichi Odahara1, Shintaro Tsukinaga1, Toyokazu Yukawa1, Jimi Mitobe1, Mikio Kajihara1, Kan Uchiyama1, Hiroshi Arakawa1, Hisao Tajiri1.   

Abstract

AIM: To investigate the association of procalcitonin (PCT) with ulcerative colitis (UC) activity.
METHODS: Serum PCT levels, C-reactive protein (CRP) levels, the erythrocyte sedimentation rate, and the white blood cell count were analyzed in 18 patients with UC and 11 healthy volunteers. Serum PCT levels were analyzed by an electrochemiluminescence immunoassay. Severity assessments were based on Truelove and Witts' severity index. Correlation of serum PCT and CRP levels with UC activity was examined. Moreover, we assessed serum PCT and CRP levels in patients with a Mayo endoscopic subscore.
RESULTS: Serum PCT levels in severe UC patients (n = 7) (0.096 ± 0.034 ng/mL) were significantly higher than in mild-to-moderate UC patients (n = 11) (0.033 ± 0.012 ng/mL) and healthy volunteers (n = 11) (0.035 ± 0.005 ng/mL) (P = 0.0005 and P < 0.0001, respectively). In addition, there was no difference in serum PCT levels between mild-to-moderate UC patients and healthy volunteers. Interestingly, patients with a Mayo endoscopic subscore of 3 points displayed significantly increased levels of serum PCT (0.075 ± 0.043 ng/mL) compared with patients with a subscore of 2 points (0.03 ± 0.011 ng/mL) (P = 0.0302). Moreover, CRP levels in patients with severe UC or a Mayo endoscopic subscore of 3 points were not significantly higher than in patients with mild-to-moderate UC or a Mayo endoscopic subscore of 3 points.
CONCLUSION: Serum PCT levels were significantly correlated with UC activity.
© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Disease activity; Procalcitonin; Severity; Ulcerative colitis

Mesh:

Substances:

Year:  2013        PMID: 24363525      PMCID: PMC3857457          DOI: 10.3748/wjg.v19.i45.8335

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

Review 1.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

Authors:  Geert D'Haens; William J Sandborn; Brian G Feagan; Karel Geboes; Stephen B Hanauer; E Jan Irvine; Marc Lémann; Philippe Marteau; Paul Rutgeerts; Jurgen Schölmerich; Lloyd R Sutherland
Journal:  Gastroenterology       Date:  2006-12-20       Impact factor: 22.682

2.  New quantitative electrochemiluminescence method (ECLIA) for interleukin-6 (IL-6) measurement.

Authors:  Belén Prieto; Diego Miguel; Marta Costa; Daniel Coto; Francisco V Alvarez
Journal:  Clin Chem Lab Med       Date:  2010-06       Impact factor: 3.694

3.  Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.

Authors:  Craig A Solem; Edward V Loftus; William J Tremaine; William S Harmsen; Alan R Zinsmeister; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2005-08       Impact factor: 5.325

4.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

5.  Low-dose hydrocortisone during severe sepsis: effects on microalbuminuria.

Authors:  Simone Rinaldi; Chiara Adembri; Serenèlla Grechi; A Raffaele De Gaudio
Journal:  Crit Care Med       Date:  2006-09       Impact factor: 7.598

6.  High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration.

Authors:  Beat Müller; Giuseppe Peri; Andrea Doni; André P Perruchoud; Regine Landmann; Fabio Pasqualini; Alberto Mantovani
Journal:  J Leukoc Biol       Date:  2002-10       Impact factor: 4.962

Review 7.  Procalcitonin as an acute phase marker.

Authors:  J Whicher; J Bienvenu; G Monneret
Journal:  Ann Clin Biochem       Date:  2001-09       Impact factor: 2.057

8.  Exogenous procalcitonin evokes a pro-inflammatory cytokine response.

Authors:  Angelike P Liappis; Kevin W Gibbs; Eric S Nylen; Bona Yoon; Richard H Snider; Baochong Gao; Kenneth L Becker
Journal:  Inflamm Res       Date:  2010-10-17       Impact factor: 4.575

Review 9.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

10.  Diagnostic value of serum procalcitonin in determining the activity of inflammatory bowel disease.

Authors:  Nevin Oruç; Omer Ozütemiz; Necla Osmanoğlu; Tankut Ilter
Journal:  Turk J Gastroenterol       Date:  2009-03       Impact factor: 1.852

View more
  9 in total

1.  Clinical importance of serum procalcitonin in ulcerative colitis patients.

Authors:  Ergenekon Karagoz; Alpaslan Tanoglu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

2.  Predictive Value of Procalcitonin in Acute Severe Ulcerative Colitis: Not Quite PerfeCT?

Authors:  Deok Whan Kim; Jeong Min An; Seong Pyo Hong; Ki Baik Hahm
Journal:  Dig Dis Sci       Date:  2019-11       Impact factor: 3.199

3.  Differentiating Clostridium difficile Colitis from Clostridium difficile Colonization in Ulcerative Colitis: A Role for Procalcitonin.

Authors:  Andrew R Reinink; Julajak Limsrivilai; Bethany A Reutemann; Tristan Feierabend; Emily Briggs; Krishna Rao; Peter D R Higgins
Journal:  Digestion       Date:  2017-10-14       Impact factor: 3.216

4.  Serum Procalcitonin as a Potential Early Predictor of Short-Term Outcomes in Acute Severe Ulcerative Colitis.

Authors:  Hui-Min Wu; Juan Wei; Jin Li; Kai Wang; Lei Ye; Ying Qi; Bo-Si Yuan; Yu-Lin Yang; Li Zhao; Zhao Yang; Miao-Fang Yang; Jian-Feng Gong; Fang-Yu Wang
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

5.  Usefulness of Measuring Serum Procalcitonin Levels in Patients with Inflammatory Bowel Disease.

Authors:  Sook Hee Chung; Hye Won Lee; Seung Won Kim; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Gut Liver       Date:  2016-07-15       Impact factor: 4.519

Review 6.  Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities.

Authors:  Giuseppe Lippi; Fabian Sanchis-Gomar
Journal:  World J Gastroenterol       Date:  2017-12-21       Impact factor: 5.742

7.  Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.

Authors:  Jin-Min Chen; Tao Liu; Shan Gao; Xu-Dong Tong; Fei-Hong Deng; Biao Nie
Journal:  World J Gastroenterol       Date:  2017-12-14       Impact factor: 5.742

8.  Clinico-bacterial and prognostic factors in patients with suspected blood stream infection and elevated serum procalcitonin levels.

Authors:  Yoko Osamura; Hideki Nishiyama; Takuya Hattori; Masaharu Gunji; Norihiro Yuasa
Journal:  Nagoya J Med Sci       Date:  2022-05       Impact factor: 0.794

9.  Bowel ultrasound enhances predictive value based on clinical indicators: a scoring system for moderate-to-severe endoscopic activities in patients with ulcerative colitis.

Authors:  Mengmeng Zhang; Huimin Zhang; Qingli Zhu; Xiaoyin Bai; Qingyang Zhou; Gechong Ruan; Wenbo Li; Li Ma; Mengsu Xiao; Hong Yang; Jiaming Qian
Journal:  Therap Adv Gastroenterol       Date:  2021-07-13       Impact factor: 4.409

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.